Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23183460 | 0.78 | KDM4E (0.48) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL23183406 | 0.71 | — | — | |
| SCHEMBL20350899 | 0.71 | ALDH1A1 (0.39) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL20340026 | 0.70 | ALDH1A1 (0.40) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL20340117 | 0.67 | KDM4E (0.57) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL20340085 | 0.65 | KDM4E (0.44) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL20340086 | 0.64 | HSD11B1 (0.33) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL20350844 | 0.63 | KDM4E (0.39) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL20350871 | 0.61 | KDM4E (0.38) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL22890710 | 0.60 | UPP1 (0.48) | KDM4EALDH1A1GLAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780812-B2 | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors | ORSOBIO, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210094916-A1 | OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS | ORSOBIO, INC. | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094916-A1 | OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS | ALDH7A1, OTC, DDC | KDM4E 1198/4885ALDH1A1 417/4885GLA 1920/4885 |
| US-11780812-B2 | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors | ALDH7A1, ACMSD, AMD1 | KDM4E 1040/4885ALDH1A1 370/4885GLA 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.